BI 691751

BI 691751 is an orally administered small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), an enzyme involved in the synthesis of leukotriene B4 (LTB4), a lipid mediator with strong proinflammatory activity. The drug was developed by Boehringer Ingelheim and investigated primarily for its potential to inhibit growth and prevent rupture of atherosclerotic plaques, thereby reducing the risk of major cardiovascular events in patients with established atherosclerotic disease. Preclinical studies demonstrated that BI 691751 could reduce plaque inflammation and LTB4 activity, but clinical development did not progress beyond Phase 1 trials, which were terminated or completed without further advancement[1][8].